US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
June 12, 2019 07:00 ET
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
Immuron Announces the Closing of Public Offering of ADSs
May 30, 2019 08:00 ET
|
Immuron Limited
MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin...
Immuron Prices Underwritten Public Offering of ADSs
May 23, 2019 21:10 ET
|
Immuron Limited
MELBOURNE, Australia,, May 23, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
April 30, 2019 14:36 ET
|
Immuron Limited
MELBOURNE, Australia, April 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
April 17, 2019 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, April 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron sales surge by 66% in the Third Quarter of FY19
April 15, 2019 09:00 ET
|
Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
April 11, 2019 10:00 ET
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
April 11, 2019 09:00 ET
|
Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...
Travelan® FY19 1st Half Update and Geographic Expansion into North America
January 29, 2019 09:30 ET
|
Immuron Limited
Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19.In the US, Travelan® exhibited double-digit growth for this period, with sales 10% higher than observed...
Immuron Receives $1.19M R&D Tax Concession Refund
January 08, 2019 02:32 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...